WHO Raises Warning Over Critical Lack of Weight-Loss Medications

Fewer than a tenth of people that would benefit from weight-loss injections like Wegovy have access to them, states the WHO as it issues its initial guidance on the therapies.

With over a billion people worldwide now classified as obese, it is urging broader and more equitable access to this class of drugs.

According to forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"Our new guidance affirms that excess weight is a lifelong illness that can be managed with holistic and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the jabs that can help people shift significant body mass, says the agency.

Skinny Jab Scarcity

Even in the current most optimistic outlook, the supply of these medications might only reach approximately 100 million people – fewer than 10% of the global need, per the health organization.

The guideline encourages governments and firms to widen availability, through strategies like patent sharing.

Exclusive production rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in multiple countries in 2026.

The Way Obesity Drugs Work

These medications mimick a biological compound to reduce digestion speed, curb appetite and increase satiety so people reduce food intake.

Patients usually begin shedding pounds after several weeks of beginning the weekly injections.

Studies suggests people may regain a significant portion after a year of halting the drug, as their typical hunger return.

Being carrying excess weight elevates your chance for experiencing health problems, including diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.